We observed AXL upregulation in FLT3/ITD AML cell lines in response to FLT3 TKI treatment, and targeting this upregulation appears to reduce much of the observed adaptive ERK reactivation in FLT3/ITD cell lines. This evidence concerns the gene FLT3 and acute myeloid leukemia.